NIH awards $5.4M grant for Phase II trial of Alzheimer's therapy

11/5/2008 | RedOrbit

The University of California, San Diego, has received a $5.4 million grant from the NIH's National Institute of Aging to conduct a Phase II clinical trial of Ceregene's CERE-110 -- a gene-therapy product that delivers nerve-growth factor in patients with Alzheimer's disease. Cergene said it expects the trial, which will involve 50 Alzheimer's patients in several clinical sites across the country, to begin early next year.

View Full Article in:

RedOrbit

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA